Distinct molecular profiles and shared drug vulnerabilities in pancreatic metastases of renal cell carcinoma
Open Access
- 20 October 2024
- journal article
- research article
- Published by Springer Nature in Communications Biology
- Vol. 7 (1) , 1-18
Abstract
Clear-cell renal cell carcinoma (ccRCC) is the most common origin of pancreatic metastases (PM). Distinct genomic aberrations, favorable prognosis, and clinical observations on high angiogenesis, and succeeding tyrosine kinase inhibitor (TKI) sensitivity have been reported in PM-ccRCC. However, no functional or single-cell studies have been conducted thus far. We recruited five PM-ccRCC patients and investigated the genomic, single-cell transcriptomic, and drug sensitivity profiles of their patient-derived cells (PDCs). The PM depicted both expected and novel genomic alterations. Further, the transcriptomics differed from both primary and metastatic ccRCC, with upregulations of the PI3K/mTOR and – supporting the clinical observations – angiogenesis pathways. Data integration at pathway level showed that transcriptomics explained drug sensitivities the best. Accordingly, PM-ccRCC PDCs shared sensitivity to many PI3K/mTOR inhibitors. Altogether, we show distinct genomic and transcriptomic signatures in PM-ccRCC, highlight the superiority of transcriptomics in interpreting drug sensitivities, and encourage the use of TKIs and PI3K/mTOR inhibitors in PM-ccRCC.Keywords
All Related Versions
Funding Information
- Viipuri Tuberculosis Foundation Biomedicum Helsinki Foundation the Sigrid Jusélius Foundation Finska Läkaresällskapet
This publication has 77 references indexed in Scilit:
- ESMO Clinical Practice Guideline update on the use of immunotherapy in early stage and advanced renal cell carcinomaAnnals of Oncology, 2021
- Cancer Predisposition Sequencing Reporter (CPSR): A flexible variant report engine for high‐throughput germline screening in cancerInternational Journal of Cancer, 2021
- Integrated analysis of multimodal single-cell dataCell, 2021
- Assessing Genomic Copy Number Alterations as Best Practice for Renal Cell Neoplasia: An Evidence-Based Review from the Cancer Genomics Consortium WorkgroupCancer Genetics, 2020
- Fibroblast as a critical stromal cell type determining prognosis in prostate cancerThe Prostate, 2019
- Comprehensive Integration of Single-Cell DataCell, 2019
- Clonal heterogeneity influences drug responsiveness in renal cancer assessed by ex vivo drug testing of multiple patient‐derived cancer cellsInternational Journal of Cancer, 2018
- Tracking Cancer Evolution Reveals Constrained Routes to Metastases: TRACERx RenalCell, 2018
- InterVar: Clinical Interpretation of Genetic Variants by the 2015 ACMG-AMP GuidelinesThe American Journal of Human Genetics, 2017
- Organoid Models of Human and Mouse Ductal Pancreatic CancerCell, 2015